Science Explorer Interactive view Map
Topic · Toxicology

Pharmacovigilance and Adverse Drug Reactions

Pharmacovigilance and Adverse Drug Reactions is a research topic within Toxicology. Science Explorer counts 14k research works in it since 1950. 17.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the study, detection, monitoring, and reporting of adverse drug reactions (ADRs) through pharmacovigilance. It covers various aspects such as signal detection, drug safety surveillance, data mining techniques, patient reporting, regulatory actions, causality assessment, and the impact of ADRs on hospital admissions.

  • Adverse Drug Reactions
  • Pharmacovigilance
  • Signal Detection
  • Drug Safety Surveillance
  • Spontaneous Reporting Systems
  • Data Mining
  • Patient Reporting
  • Regulatory Actions
  • Causality Assessment
  • Hospital Admissions
Research works
14k
fractional, since 1950
In the world top 10%
2.4k
per year above
Top-10% rate
17.1%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+24%
the tick is no change

Which countries lead Pharmacovigilance and Adverse Drug Reactions research?

By volume, the United States and China publish the most (609 and 489 works in 2022–2025).

By volume, 2022–2025

  1. 1 United States 609 works
  2. 2 China 489 works
  3. 3 India 338 works
  4. 4 United Kingdom 178 works
  5. 5 France 146 works
  6. 6 Japan 131 works
  7. 7 Germany 96 works
  8. 8 Spain 87 works
  9. 9 Canada 79 works
  10. 10 Australia 78 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 27.3%China: 21.9%India: 15.1%United Kingdom: 8.0%6 others listed: 27.6%27%largest
United States609 · 27.3%China489 · 21.9%India338 · 15.1%United Kingdom178 · 8.0%6 others listed616 · 27.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Pharmacovigilance and Adverse Drug Reactions research?

By volume in 2022–2025, Harvard University publishes the most Pharmacovigilance and Adverse Drug Reactions research, followed by Sichuan University and Inserm.

By volume, 2022–2025

  1. 1 Harvard UniversityUnited States 12 works
  2. 2 Sichuan UniversityChina 11 works
  3. 3 InsermFrance 11 works
  4. 4 University of North Carolina at Chapel HillUnited States 10 works
  5. 5 Klinik und Poliklinik für Psychosomatik und PsychotherapieGermany 9 works
  6. 6 Hindu College of PharmacyIndia 9 works
  7. 7 Center for Drug Evaluation and ResearchUnited States 9 works
  8. 8 United States Food and Drug AdministrationUnited States 9 works
  9. 9 Delhi Pharmaceutical Science and Research UniversityIndia 9 works
  10. 10 Brigham and Women's HospitalUnited States 8 works

Where is Pharmacovigilance and Adverse Drug Reactions research done?

The largest centres of Pharmacovigilance and Adverse Drug Reactions research in 2022–2025 are Beijing (China), London (United Kingdom), Seoul (South Korea) and Tokyo (Japan).

Largest cities, 2022–2025

  1. 1 Beijing China 54 works
  2. 2 London United Kingdom 48 works
  3. 3 Seoul South Korea 43 works
  4. 4 Tokyo Japan 43 works
  5. 5 Paris France 43 works
  6. 6 Boston United States 33 works
  7. 7 Guangzhou China 31 works
  8. 8 Chengdu China 31 works
  9. 9 Shanghai China 29 works
  10. 10 New Delhi India 27 works
See Pharmacovigilance and Adverse Drug Reactions on the map

Where is the best place to study Pharmacovigilance and Adverse Drug Reactions?

Among universities, judged by research, Harvard University, Sichuan University and Delhi Pharmaceutical Science and Research University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.74%fractional works in this node (log) →share in the world top 10% →Harvard University: 12, 26.3%Sichuan University: 11, 31.7%Delhi Pharmaceutical Science and Research University: 8, 19.6%Hindu College of Pharmacy: 9, 7.3%University of North Carolina at Chapel Hill: 10, 13.8%Sichuan UniversityHarvard UniversityDelhi Pharmaceutical…Hindu College of Pha…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Harvard UniversityUnited States 62.326.3%3.1×12 +34.6%
2 Sichuan UniversityChina 52.331.7%2.1×11 +14.5%
3 Delhi Pharmaceutical Science and Research UniversityIndia 48.019.6%86.4×8 -13.3%
4 Hindu College of PharmacyIndia 43.17.3%28.3×9 —
5 University of North Carolina at Chapel HillUnited States 38.213.8%1.9×10 +103.4%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Pharmacovigilance and Adverse Drug Reactions research growing?

Output in 2018–2022 was 24% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Pharmacovigilance and Adverse Drug Reactions.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.